Key facts
- Starna Therapeutics’s last known valuation is $87.5M (Apr 2022).
- It has raised $75.7M; the latest was Early Stage VC in Apr 2026.
- Notable investors include GL Ventures, Source Code Capital, Tencent Investment, Hony Capital, Primavera Capital Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Starna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Starna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starna Therapeutics
Developer of nucleic acid-based therapeutic formulation designed for targeted delivery applications. The company offers lipid nanoparticle systems, mRNA synthesis, and formulation technologies to support extrahepatic delivery of RNA molecules, serving biotechnology firms and clinical researchers to access precision-targeted treatments for respiratory infections, tumours, and metabolic disorders through scalable preclinical and clinical development pipelines.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- starnatx.com/
- Ownership
- Privately Held (backing)
Starna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.